- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Advice for Investors Entering Weight-Loss Market
In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, shares advice for investors and financiers who are considering entering the weight-loss medication market.
What advice do you have for investors and financiers who are considering entering the weight-loss medication market?
First of all, don't believe the hype. It's calmed down a little now. But remember, when last summer when you had, you know, crazy things like news would come out and the stock of fast food companies would go down? You know, nothing is that revolutionary. So that's calmed down a little bit. But then I hearken back to what I was saying, there's so many companies in this field, not all of them come yet. So, I think you have to really do your homework and to pick and choose who are going to be the winners. And unlikely that you're going to have, you know, a small new company get established, you may have some of these companies that are small and are working on products, they will link up with the established players, or Lilly or novo, or one of the bigger drug companies that are eager to get into this market. And you've already seen several examples of that happening. So, there will be some winners and there'll be a lot of losers. So, if you're an investor, do your homework well. Or makes or place a lot of bets and hope that a few of them pay off.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
